Marvel Biosciences Corp. (MRVL.V)
- Previous Close
0.1350 - Open
0.1350 - Bid 0.1300 x --
- Ask 0.1400 x --
- Day's Range
0.1350 - 0.1350 - 52 Week Range
0.0100 - 0.1900 - Volume
4,000 - Avg. Volume
45,463 - Market Cap (intraday)
5.371M - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company's lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson's disease. It targets diseases, such as depression, Alzheimer's disease, and liver fibrosis due to non-alcoholic steatohepatitis. The company is headquartered in Calgary, Canada.
marvelbiotechnology.comRecent News: MRVL.V
Performance Overview: MRVL.V
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRVL.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRVL.V
Valuation Measures
Market Cap
5.37M
Enterprise Value
6.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-219.08%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.51M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
577.67k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-225.83k
Company Insights: MRVL.V
MRVL.V does not have Company Insights